Darusentan (LU-135252; HMR-4005) is an
endothelin receptor antagonist
An endothelin receptor antagonist (ERA) is a drug that blocks endothelin receptors.
Three main kinds of ERAs exist:
* selective ETA receptor antagonists (sitaxentan, ambrisentan, atrasentan, BQ-123, zibotentan, edonentan), which affect endothel ...
.
Gilead Colorado, a subsidiary of
Gilead Sciences
Gilead Sciences, Inc. () is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and ...
, under license from
Abbott Laboratories
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known dr ...
, is developing darusentan for the potential treatment of uncontrolled
hypertension.
In June 2003,
Myogen licensed the compound from Abbott for its application in the cancer field.
In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacy
phase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study, but was terminated because the study did not reach its primary endpoints.
See also
*
Ambrisentan
Ambrisentan (U.S. trade name Letairis; E.U. trade name Volibris; India trade name Pulmonext by MSN labs) is a drug indicated for use in the treatment of pulmonary hypertension.
The peptide endothelin constricts muscles in blood vessels, incr ...
References
Endothelin receptor antagonists
Barbiturates
Experimental drugs
Lactims
Carboxylic acids
Diphenylmethanol ethers
Aromatic ethers
{{antineoplastic-drug-stub